Leukemic cell growth inhibiting method

• US 6,465,512 B2
• Filed: 12/12/2000
• Issued: 10/15/2002
• Est. Priority Date: 12/13/1999
• Status: Expired due to Fees

• Current Assignee: National Institute of Advanced Industrial Science and Technology (Government of Japan)
• Original Assignee: National Institute of Advanced Industrial Science and Technology (Government of Japan)
• Inventors: Fuke, Yoko, Nakamura, Osamu, Ohba, Hideki, Yasuda, Seiji
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US09/733,947
• Publication Number:
  US 20020022655A1
• Time in Patent Office: 672 Days
• Field of Search: 514/514, 514/885, 514/908
• US Class Current: 514/514
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed is a method for growth inhibition of human leukemic cells or therapeutic treatment method of a leukemic patient by using a medicament of which the effective ingredient is a methylsulfinylalkyl isothiocyanate such as 4-(methylsulfinyl)butyl isothiocyanate and 6-(methylsulfinyl)hexyl isothiocyanate, which can be prepared by extraction from the tissues of certain plants and can induce apoptosis in human leukemic cells. This medicament compound is little growth-inhibitive against normal cells as compared with leukemic cells, so that a remarkable therapeutic effect can be expected.

Claims

1. A method for growth inhibition against leukemic cells which comprises:

bringing the leukemic cells into contact with a leukemic cell growth inhibitor which is a methylsulfinylalkyl isothiocyanate represented by the general formula

2. The method for growth inhibition against leukemic cells as claimed in claim 1 in which the leukemic cell growth inhibitor is 4-(methylsulfinyl)butyl isothiocyanate.

3. The method for growth inhibition against leukemic cells as claimed in claim 1 in which the leukemic cell growth inhibitor is 6-(methylsulfinyl)hexyl isothiocyanate.

4. A therapeutic treatment method of a leukemic patient which comprises administrating the patient with a leukemic cell growth inhibitor which is a methylsulfinylalkyl isothiocyanate represented by the general formula

5. The therapeutic treatment method of a leukemic patient as claimed in claim 4 in which the administration of the patient with the leukemic cell growth inhibitor is conducted parenterally.

6. The therapeutic treatment method of a leukemic patient as claimed in claim 4 in which the administration dose of the patient with the leukemic cell growth inhibitor is in the range from 0.01 to 10 mg/kg body weight per day.

7. The therapeutic treatment method of a leukemic patient as claimed in claim 4 in which the leukemic cell growth inhibitor is 4-(methylsulfinyl)butyl isothiocyanate.

8. The therapeutic treatment method of a leukemic patient as claimed in claim 4 in which the leukemic cell growth inhibitor is 6-(methylsulfinyl)hexyl isothiocyanate.